What is the European Commission reviewing?

The European Commission is reviewing safety information on Eisai and Biogen's Alzheimer's drug Leqembi.

When was the safety information made available?

The safety information was made available after November, following the regulator's recommendation for approval of the drug.

Who reported on the safety review?

The article was reported by Bhanvi Satija in Bengaluru.

Editorial & Advertiser disclosure

Global Banking & Finance Review® is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

Home > Headlines > Europe to review safety data for Eisai-Biogen Alzheimer's drug

Headlines

Europe to review safety data for Eisai-Biogen Alzheimer's drug

Published by Global Banking & Finance Review®

Posted on January 31, 2025

1 min read

Last updated: January 26, 2026

European Commission evaluates safety data for Eisai-Biogen Alzheimer's drug - Global Banking & Finance Review — The image represents the European Commission's assessment of safety data for Leqembi, Eisai and Biogen's Alzheimer's drug. This review is crucial for early Alzheimer's disease patients.

Europe to review safety data for Eisai-Biogen Alzheimer's drug

Quick Summary

European Commission to Assess Safety Data for Leqembi Alzheimer's Drug

Key Takeaways

Frequently Asked Questions about Europe to review safety data for Eisai-Biogen Alzheimer's drug